SCHEMBL1049638

SCHEMBL1049638

CNC(=O)c1ccc(Nc2nc(-c3ccc(C)nc3C)cc3cc[nH]c(=O)c23)cc1

nearest known ligand 0.52

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ZAP70 P43403 15/20 0.52
TYK2 P29597 1/20 0.43
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
RXFP1 Q9HBX9 1/20 0.40
PTK2 Q05397 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1045570 0.83 ZAP70 (0.66) ZAP70TYK2JAK2JAK1PTK2
SCHEMBL1044331 0.80 ZAP70 (0.77) ZAP70TYK2JAK2JAK1PTK2
SCHEMBL12928885 0.80 ZAP70 (0.62) ZAP70TYK2JAK2JAK1RXFP1
SCHEMBL1049746 0.78 ZAP70 (0.58) ZAP70TYK2JAK2JAK1PTK2
SCHEMBL1047740 0.77 ZAP70 (0.57) ZAP70TYK2JAK2JAK1
SCHEMBL1046707 0.77 ZAP70 (0.64) ZAP70TYK2JAK2JAK1PTK2
SCHEMBL12929757 0.76 ZAP70 (0.60) ZAP70TYK2JAK2JAK1
SCHEMBL1045549 0.76 ZAP70 (0.66) ZAP70TYK2JAK2JAK1PTK2
SCHEMBL1048423 0.76 ZAP70 (0.47) ZAP70TYK2JAK2JAK1
SCHEMBL1046634 0.75 ZAP70 (0.48) ZAP70TYK2JAK2PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US claimed
CN-101990539-A Compounds and compositions as kinase inhibitors IRM LLC 2011-03-23 CN claimed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US claimed
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US disclosed
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US disclosed
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US disclosed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US disclosed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US disclosed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US disclosed
EP-2238137-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-10-13 EP disclosed
WO-2009097287-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FYN, SYK, RET ZAP70 4/4885TYK2 70/4885JAK2 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.